Literature DB >> 9195365

Hepatitis B infection and changes in interferon-alpha and -gamma production in patients with systemic lupus erythematosus in Taiwan.

C L Lu1, S T Tsai, C Y Chan, S J Hwang, C Y Tsai, J C Wu, R H Lu, B C Lin, S D Lee.   

Abstract

According to previous reports, the prevalence of hepatitis B virus (HBV) infection in patients with systemic lupus erythematosus (SLE) is varied. There has been no report on Taiwan, a hyperendemic area for HBV infection. Furthermore, impaired production of interferon (IFN) in peripheral blood mononuclear cells (PBMC) has been reported to be potentially pathogenic to both chronic HBV infection and SLE. However, the production of IFN in patients with both diseases coexisting is unknown. The aims of this study were to evaluate the prevalence of HBV infection in lupus patients in Taiwan and to measure the production of IFN in patients with both diseases coexisting. One hundred and seventy-three consecutive lupus patients and a control group of 692 age- and sex-matched healthy subjects were included for evaluation of the prevalence of HBsAg. Four groups of subjects (patients with SLE and HbsAg, SLE, chronic hepatitis B and normal controls) were selected for evaluation of the in vitro production of IFN-alpha and -gamma. Six (3.5%) of the 173 SLE patients were positive for HBsAg, which was significantly lower than that of controls (14.7%; P < 0.0001). Patients with coexistent SLE and chronic HBV infection had less lupus activity, including less proteinuria (P = 0.02) and a lower serum titre of anti-double stranded DNA antibodies (anti-dsDNA; P = 0.04), than HBsAg-negative lupus patients. The in vitro production of IFN-alpha in patients with chronic hepatitis B was significantly lower than in those patients with SLE or in the normal control group (P < 0.01). The yields of IFN-alpha and -gamma in patients with coexistent SLE and chronic HBV infection were significantly different from those patients with SLE alone (P < 0.05), but close to those of patients with chronic HBV infection. In conclusion, the prevalence of HBsAg carriers is significantly lower in lupus patients in Taiwan. Patients with coexistent SLE and chronic HBV infection had less lupus activity. Interferon-alpha and -gamma may play a role in the above phenomenon.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9195365     DOI: 10.1111/j.1440-1746.1997.tb00420.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Clinical significance of chronic hepatitis B virus infection in patients with primary Sjögren's syndrome.

Authors:  Ming-Han Chen; Liang-Tsai Hsiao; Ming-Huang Chen; Chang-Youh Tsai; Yi-Hsiang Huang; Chung-Tei Chou
Journal:  Clin Rheumatol       Date:  2011-08-02       Impact factor: 2.980

2.  Altered mRNA levels of MOV10, A3G, and IFN-α in patients with chronic hepatitis B.

Authors:  Zhi-Wei Song; Yan-Xiu Ma; Bao-qing Fu; Xu Teng; Si-Jia Chen; Wei-Zhen Xu; Hong-Xi Gu
Journal:  J Microbiol       Date:  2014-05-29       Impact factor: 3.422

3.  Hepatitis B carrier state among SLE patients: case-control study.

Authors:  Omer Gendelman; Naim Mahroum; Doron Comaneshter; Pnina Rotman-Pikielny; Arnon D Cohen; Howard Amital; Michael Sherf
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

4.  Management of hepatitis B reactivation in patients with lupus nephritis.

Authors:  Kai-Chung Tse; Susan Yung; Colin Tang; Terence Pok-Siu Yip; Tak Mao Chan
Journal:  Rheumatol Int       Date:  2009-01-22       Impact factor: 2.631

5.  Hepatitis B Virus Infection Rate and Distribution in Chinese Systemic Lupus Erythematosus Patients.

Authors:  Xumin Chen; Lingyao Hong; Wang Zhang; Meng Yuan; Qiongqiong Yang; Haiping Mao; Wei Chen; Xueqing Yu
Journal:  Med Sci Monit       Date:  2015-07-06

6.  Prevalence of hepatitis B virus and hepatitis C virus infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis.

Authors:  Sen Wang; Yuxin Chen; Xuejing Xu; Wei Hu; Han Shen; Junhao Chen
Journal:  Oncotarget       Date:  2017-11-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.